EUCTR2017-001710-28-BE进行中（未招募）1 期
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 215
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects, age 18 years or older.
- •2. Presence of measurable disease that has been confirmed by histology or cytology. Myelofibrosis subjects must have palpable spleen of = 5 cm below the left subcostal margin on physical examination at the screening visit.
- •3. The following malignancy types will be included in each of the treatment groups:
- •Part 1 (Dose Escalation)
- •Treatment Group A: AML or myelodysplastic syndrome (MDS)
- •Treatment Group B: SCLC (other solid tumors, eg, endocrine tumors, are allowed with medical monitor approval)
- •Part 2 (Dose Expansion)
- •Treatment Group A1: Relapsed/refractory AML or MDS
- •Treatment Group A2: MF (PMF, PPV-MF, and PET-MF)
- •Treatment Group B1: SCLC
- •Treatment Group B2: Ewing's sarcoma and poorly differentiated neuroendocrine tumors
- •Parts 3 and 4 (Combination Dose Escalation/Expansion)
- •Treatment Group C/C1: Relapsed/refractory AML
- •Treatment Group D/D1: Subjects with newly diagnosed, treatment-naive AML who are unfit to tolerate standard intensive chemotherapy at study entry
- •Treatment Group E/E1: SCLC previously progressed on platinum-based treatment
- •4. Subjects must meet specific disease and treatment criteria as follows:
- •- TG A/A1/A2, TG B/B1/B2, C/C1, and TG E/E1: The subject must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
- •- TG A2: The subjects must have confirmed diagnosis of PMF, PPV-MF, or PET-MF according to revised WHO 2016 criteria.
- •- TG D/D1: Subjects with newly diagnosed, treatment-naive AML who are unfit to tolerate standard intensive chemotherapy at study entry based on at least 1 of the following criteria:
- •? Age = 75 years old
- •? History of congestive heart failure (CHF) or documented ejection fraction (EF) = 50%
- •? Pulmonary disease with DLCO = 65% or FEVI = 65%, or dyspnea at rest or requiring oxygen
- •? Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy
- •- TG E/E1: The subjects in TG E must have previously received platinum-based therapy, but additional lines of therapies are allowed. The subjects in TG E1 must not have received more than 1 previous line of therapy for locally advanced or metastatic SCLC. The previous line of therapy must be a platinum-based therapy, and the subjects must have progressed on or after this treatment.
- •5. Willingness to undergo a pretreatment bone marrow biopsy or aspirate (AML/MDS/MF) during screening (may be waived with medical monitor approval). For subjects with solid malignancies, must have baseline archival tumor specimen available: a tumor block or approximately 15 slides from biopsy or resection of primary tumor or metastasis that are < 2 years old (specimens > 2 years old may be accepted with medical monitor approval).
- •Please refer to study protocol for further inclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 65
排除标准
- •1. Receipt of anticancer medications, anticancer therapies, or investigational drugs within the following interval before the first administration of study drug (requirement may be waived with medical monitor approval):
- •a. < 5 half-lives or 14 days, whichever is longer, for any investigational agent
- •b. < 5 half-lives for all other anticancer medications
- •c. < 6 weeks for mitomycin-C or nitrosoureas
- •2. Any unresolved toxicity = Grade 2 from previous anticancer therapy except for stable chronic toxicities (= Grade 2) not expected to resolve.
- •3. All treatment groups: prior receipt of an LSD1 inhibitor therapy. Parts 3 and 4 TG E/E1: prior receipt of anti–programmed cell death-1, anti–programmed death ligand 1, or anti–PD-L2 antibody.
- •4. Any of the following laboratory results at screening without transfusions and hematopoietic growth factor support in solid tumors (no lower limits in AML and MDS, or in MF with medical monitor approval):
- •Absolute neutrophil count (× 109/L): < 1.5
- •Hemoglobin (g/dL): < 9.0
- •Platelet count (× 109/L): < 100
- •5. Laboratory and medical history parameters outside Protocol-defined range unless associated with primary malignancy or metastatic disease and with medical monitor approval:
- •a. Total bilirubin > 1.5 × institutional upper limit of normal (ULN) if no liver metastases or > 3 × ULN in the presence of liver metastases or presence of documented Gilbert syndrome (unconjugated hyperbilirubinemia).
- •b. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.0 × institutional ULN.
- •c. Creatinine clearance < 60 mL/min based on the institutional formula.
- •Please refers to study protocol for further exclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced MalignanciesPotential subjects include those with advanced or metastatic malignancies who are ineligible for all therapeutic options that are standard of care or known to confer clinical benefit, or who refuse these treatments.MedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2017-001710-28-NLIncyte Corporation215
已完成
不适用
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced MalignanciesNL-OMON48925Incyte Biosciences UK Ltd10
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesEUCTR2017-002641-29-FRIncyte Corporation420
招募中
1 期
Study of DSP-5336 in Patients with Adult Acute Leukemia.JPRN-jRCT2031210594Tada Tomohiro100
招募中
1 期
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias. Various doses of SNDX-5613 will be investigated.EUCTR2020-004104-34-ITSYNDAX PHARMACEUTICALS, INC.333